Related Experiment Videos
Prognostication in advanced cancer: a study examining an inflammation-based score
Michael Partridge1, Marie Fallon, Caroline Bray
1St. Columba's Hospice, Edinburgh, United Kingdom.
Journal of Pain and Symptom Management
|June 27, 2012
Summary
The modified Glasgow Prognostic Score (mGPS), using C-reactive protein and albumin, effectively predicts mortality in advanced cancer patients. This inflammation-based score aids in end-of-life care planning and treatment decisions.
Area of Science:
- Oncology
- Clinical Pathology
Background:
- Prognostication in advanced cancer is complex.
- Systemic inflammation biomarkers, C-reactive protein and albumin, are combined into the modified Glasgow Prognostic Score (mGPS).
- The mGPS has been utilized for prognostication across diverse cancer types.
Purpose of the Study:
- To evaluate the utility of the inflammation-based prognostic score (mGPS) for prognostication in patients with advanced cancer.
Main Methods:
- Cancer patients with recorded C-reactive protein and albumin levels were assigned an mGPS (0-2).
- Statistical analyses included Jonckheere-Terpstra and Chi-squared tests for group comparisons.
- Survival outcomes were assessed using Kaplan-Meier and multivariate Cox regression models.
Main Results:
- The study included 296 patients; 102 had recorded biomarkers.
- The mGPS significantly predicted mortality (P=0.014), independent of other clinical factors.
- Patients with mGPS 2 faced 2.7 times higher mortality risk than those with mGPS 0 (P=0.011).
- Survival rates at 2 and 4 weeks were 86.1% and 74.3% for patients with mGPS < 2.
Conclusions:
- The mGPS shows potential utility in end-of-life prognostication.
- Biomarkers like the mGPS can support clinical decisions regarding intensive treatments.
- The mGPS may facilitate improved end-of-life care planning.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...